The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair ... Adverse events associated with Omlyclo include injection site reactions, fever, headache, dizziness and arthralgia.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...